论文部分内容阅读
目的:评价同步化疗加后程适形放射治疗III期非小细胞肺癌的疗效和并发症。方法:64例III期非小细胞肺癌患者随机分为二组(适形组与对照组),每组32例,先采用6/15MV-X线常规外放疗DT40Gy后,适形组采用三维适形放疗2.5Gy~3Gy/次,1次/d,累计量68Gy~72Gy;对照组采用常规外放疗2Gy/次,累计量64Gy~66Gy。化疗采用EP方案(足叶乙甙和顺铂)。结果:适形组与对照组1、2年生存率分别为87.5%、56.3%和65.6%、34.4%(P<0.05);局部制率分别为90.6%、81.3%和65.6%、53.1%(P<0.05)。结论:同步化疗加后程适形放射治疗可提高III期非小细胞肺癌的生存率,并未增加毒副反应。
OBJECTIVE: To evaluate the efficacy and complications of concurrent chemoradiotherapy plus posterior conformal radiation therapy for stage III non-small cell lung cancer. Methods: Sixty-four patients with stage III non-small cell lung cancer were randomly divided into two groups (conformal group and control group) with 32 cases in each group. After DT40Gy with 6 / 15MV-X conventional external radiotherapy, Radiotherapy 2.5Gy ~ 3Gy / times, 1 time / d, the cumulative amount of 68Gy ~ 72Gy; control group conventional radiotherapy 2Gy / times, the cumulative amount of 64Gy ~ 66Gy. Chemotherapy with EP regimen (etoposide and cisplatin). Results The 1-year and 2-year survival rates of conformal group and control group were 87.5%, 56.3% and 65.6%, 34.4% (P <0.05), respectively. The local system rates were 90.6%, 81.3% and 65.6%, 53.1% P <0.05). Conclusions: Chemotherapy combined with posterior conformal radiation therapy can improve the survival rate of stage III non-small cell lung cancer without increasing the toxicity.